<DOC>
	<DOCNO>NCT00003011</DOCNO>
	<brief_summary>RATIONALE : Marimastat may stop growth lung cancer stop blood flow tumor . It yet know marimastat effective treatment small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness marimastat placebo follow chemotherapy treat patient small cell lung cancer .</brief_summary>
	<brief_title>Marimastat Following Chemotherapy Treating Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether treatment oral matrix metalloproteinase inhibitor ( MMPI ) marimastat prolongs overall survival time progression patient small cell lung cancer achieve complete partial remission first line chemotherapy , without radiotherapy . II . Determine tolerability toxicity prolong administration marimastat patient small cell lung cancer . III . Determine effect prolong administration marimastat quality life patient small cell lung cancer . OUTLINE : This randomize , double blind , multicenter , placebo control study . Patients stratified stage disease diagnosis , response prior chemotherapy/radiotherapy , type thoracic radiotherapy , cooperative group . Patients randomize two group . Half patient take marimastat orally twice day ( breakfast even meal ) ; half take placebo orally twice day ( breakfast even meal ) . Treatment continue 2 year document disease recurrence progression institution anticancer treatment , occurrence unacceptable toxicity , initiation anticoagulant treatment , development intercurrent illness . All patient follow every 6 month death . PROJECTED ACCRUAL : The planned sample size 360 , equal number patient arm , accrue rate 240 responder per year ( result accrual period approximately 1.5 year ) . The total duration study estimate 2.3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Marimastat</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven small cell lung cancer Complete response ( CR ) partial response ( PR ) follow first line chemotherapy require Chest xray show CR PR require . No document prior brain metastasis PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Effective contraception use men woman reproductive potential No prior malignancy within 5 year except : Adequately treat nonmelanomatous skin cancer Adequately treat carcinoma situ cervix No concurrent malignancies No prior diagnosis breast cancer , melanoma , hypernephroma No major medical illness would preclude prolonged administration marimastat require follow No active peptic ulceration symptom suggestive diagnosis No grade 3 4 musculoskeletal disorder PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : One prior induction combination chemotherapy regimen require Must complete prior randomization Hematologically recover randomization Minimum 4 cycle require No change regimen due progression No chemotherapy within 28 day prior randomization thoracic radiation give prior concurrent chemotherapy No prior marimastat Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Must complete prior randomization Last dose radiation treatment must within 714 day prior randomization thoracic radiation and/or prophylactic cranial irradiation give completion chemotherapy If severe esophagitis precludes administration oral medication , randomization may within 21 day radiation therapy Surgery : No surgery within 2 week prior randomization Prior complete resection tumor allow Other : No investigational agent within 4 week prior study , none plan No concurrent coumarin anticoagulant coumarin anticoagulant within 4 week prior randomization No concurrent antitumor treatment</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>